ENYO PHARMA

Hepatitis B, a significant global health challenge, is expected to see market growth due to increasing prevalence and awareness. Key companies like Gilead Sciences and Brii Biosciences are advancing treatments through clinical trials. The market, driven by antiviral medications, anticipates a surge with new pipeline products. Vaccination remains the most effective prevention method.

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.